Home LiteratureArticle Details
PMID: 31468240 Published · epublish English Journal Article Review

Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Current urology reports ·Vol. 20 ·No. 10 ·2019-08-29 ·Pages 56

Karivedu V, Jain AL, Eluvathingal TJ, Sidana A

Abstract

The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC. Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.

Keywords
Fluorodeoxyglucose (FDG) Metabolically active renal cell carcinoma Metastases Positron emission tomography/computed tomography (PET/CT) Restaging Therapy monitoring
MeSH Terms
Carcinoma, Renal Cell/diagnostic imaging,metabolism,pathology Fluorine Radioisotopes Fluorodeoxyglucose F18 Humans Kidney Neoplasms/diagnostic imaging,metabolism,pathology Neoplasm Staging Positron Emission Tomography Computed Tomography Positron-Emission Tomography Radiopharmaceuticals
Chemicals
Fluorine Radioisotopes Radiopharmaceuticals Fluorodeoxyglucose F18 Fluorine-18
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Karivedu Vidhya
Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA.
Jain Amit L
Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Eluvathingal Thomas J
Department of Radiology, University of Cincinnati, Cincinnati, OH, USA.
Sidana Abhinav
Division of Urology, University of Cincinnati, Cincinnati, OH, USA. sidanaav@ucmail.uc.edu. | Division of Urology, University of Cincinnati Cancer Institute, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0589, Cincinnati, OH, 45267, USA. sidanaav@ucmail.uc.edu.
References (84)
84 references, click to expand
  1. Metastatic renal cell carcinoma.
    Curr Treat Options Oncol. 2003 Oct;4(5):385-90 PMID: 12941198
  2. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies.
    J Nucl Med. 2006 Nov;47(11):1803-7 PMID: 17079813
  3. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography.
    BJU Int. 2005 Sep;96(4):540-6 PMID: 16104907
  4. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.
    BMC Cancer. 2019 Apr 2;19(1):298 PMID: 30940117
  5. 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma.
    J Nucl Med. 2017 Jun;58(6):905-910 PMID: 28082434
  6. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
    J Clin Oncol. 2009 Feb 1;27(4):535-41 PMID: 19075273
  7. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
    Cell Cycle. 2010 Oct 15;9(20):4183-9 PMID: 20953139
  8. The metabolic basis of kidney cancer.
    Semin Cancer Biol. 2013 Feb;23(1):46-55 PMID: 22705279
  9. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
    BMC Cancer. 2014 Jun 02;14:390 PMID: 24885730
  10. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.
    J Clin Oncol. 2018 Oct 29;:JCO2018792309 PMID: 30372395
  11. Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.
    Mol Imaging Biol. 2009 Nov-Dec;11(6):434-8 PMID: 19449079
  12. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
    Cancer Med. 2013 Aug;2(4):545-52 PMID: 24156027
  13. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer.
    Int J Urol. 2002 Jan;9(1):15-8 PMID: 11972644
  14. The genetic basis of kidney cancer: a metabolic disease.
    Nat Rev Urol. 2010 May;7(5):277-85 PMID: 20448661
  15. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Ann Oncol. 2015 Oct;26(10):2113-8 PMID: 26202597
  16. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.
    Ann Oncol. 2012 Apr;23(4):973-80 PMID: 21890909
  17. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Clin Cancer Res. 2008 Aug 1;14(15):4726-34 PMID: 18676741
  18. Inherited susceptibility to uterine leiomyomas and renal cell cancer.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 PMID: 11248088
  19. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.
    J Cancer Res Clin Oncol. 2002 Sep;128(9):503-6 PMID: 12242515
  20. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
    Clin Cancer Res. 2011 Sep 15;17(18):6021-8 PMID: 21742806
  21. Recommendations on the use of 18F-FDG PET in oncology.
    J Nucl Med. 2008 Mar;49(3):480-508 PMID: 18287273
  22. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Clin Nucl Med. 2014 Jun;39(6):e320-4 PMID: 24566409
  23. Detection of synchronous primary breast and prostate cancer by F-18 fluorocholine PET/CT.
    Clin Nucl Med. 2010 Feb;35(2):128-9 PMID: 20090467
  24. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Nucl Med Commun. 2011 Apr;32(4):265-72 PMID: 21301376
  25. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
    J Nucl Med. 2010 Nov;51(11):1707-15 PMID: 20956472
  26. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.
    Am J Hum Genet. 2004 Jan;74(1):153-9 PMID: 14685938
  27. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.
    Cancer Imaging. 2012 Oct 26;12:464-74 PMID: 23108238
  28. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
    J Nucl Med. 2011 Jan;52(1):81-9 PMID: 21149473
  29. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
    Clin Nucl Med. 2015 Dec;40(12):936-40 PMID: 26164183
  30. Epidemiology, clinical staging, and presentation of renal cell carcinoma.
    Urol Clin North Am. 2008 Nov;35(4):581-92; vi PMID: 18992612
  31. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.
    Nucl Med Commun. 2017 Feb;38(2):156-163 PMID: 27824726
  32. Clinical applications of PET in oncology.
    Radiology. 2004 May;231(2):305-32 PMID: 15044750
  33. Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience.
    World J Nucl Med. 2015 Jan-Apr;14(1):36-40 PMID: 25709543
  34. [Positron emission tomography in diagnosis of renal cell carcinoma].
    Urologe A. 1996 Mar;35(2):146-50 PMID: 8650849
  35. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
    J Urol. 2001 Sep;166(3):825-30 PMID: 11490227
  36. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour.
    EJNMMI Res. 2016 Dec;6(1):76 PMID: 27771904
  37. Cancer statistics, 2019.
    CA Cancer J Clin. 2019 Jan;69(1):7-34 PMID: 30620402
  38. In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET.
    Asia Ocean J Nucl Med Biol. 2014 Spring;2(1):3-11 PMID: 27408853
  39. The VHL/HIF axis in clear cell renal carcinoma.
    Semin Cancer Biol. 2013 Feb;23(1):18-25 PMID: 22705278
  40. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Oncogene. 2005 Feb 3;24(6):1043-52 PMID: 15592504
  41. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
    Clin Cancer Res. 2011 Dec 15;17(24):7634-44 PMID: 22038997
  42. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
    Nucl Med Commun. 2002 Mar;23(3):229-36 PMID: 11891480
  43. Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer.
    Ann Nucl Med. 2018 Dec;32(10):658-668 PMID: 30120698
  44. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
    Cancer. 2018 Jul 1;124(13):2785-2800 PMID: 29786848
  45. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
    Lancet Oncol. 2007 Apr;8(4):304-10 PMID: 17395103
  46. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.
    Clin Nephrol. 2002 Jan;57(1):56-62 PMID: 11837802
  47. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
    J Clin Oncol. 2005 Oct 20;23(30):7445-53 PMID: 16157939
  48. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.
    J Urol. 2004 May;171(5):1806-9 PMID: 15076281
  49. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
    Eur J Radiol. 2011 Jul;79(1):29-35 PMID: 20015602
  50. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.
    Radiol Oncol. 2014 Jul 10;48(3):219-27 PMID: 25177235
  51. Comprehensive molecular characterization of clear cell renal cell carcinoma.
    Nature. 2013 Jul 4;499(7456):43-9 PMID: 23792563
  52. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
    J Nucl Med. 2011 Jul;52(7):1048-55 PMID: 21680694
  53. Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
    Clin Cancer Res. 2011 Sep 15;17(18):5841-3 PMID: 21926167
  54. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
    Eur Urol. 2018 Sep;74(3):257-260 PMID: 29730017
  55. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors.
    Clin Nucl Med. 2006 Dec;31(12):788-9 PMID: 17117073
  56. Immunohistochemical localization of glucose transporters in human renal cell carcinoma.
    J Urol. 1995 Mar;153(3 Pt 1):798-801 PMID: 7861542
  57. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
    Cancer Cell. 2005 Aug;8(2):143-53 PMID: 16098467
  58. Therapeutic Strategies for Hereditary Kidney Cancer.
    Curr Oncol Rep. 2016 Aug;18(8):50 PMID: 27325049
  59. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    BMC Cancer. 2012 May 02;12:162 PMID: 22551397
  60. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    BJU Int. 2009 Mar;103(5):615-9 PMID: 19007371
  61. Role of FDG PET-CT in recurrent renal cell carcinoma.
    Nucl Med Commun. 2010 Oct;31(10):844-50 PMID: 20661166
  62. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    J Clin Oncol. 2003 Nov 1;21(21):3995-4000 PMID: 14581422
  63. Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study.
    BMC Cancer. 2017 Jun 2;17(1):392 PMID: 28578690
  64. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
    Nucl Med Commun. 2009 Jul;30(7):519-24 PMID: 19522059
  65. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.
    Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1236-45 PMID: 12845486
  66. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.
    Hell J Nucl Med. 2013 Jan-Apr;16(1):19-24 PMID: 23529389
  67. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
    Nat Genet. 2002 Apr;30(4):406-10 PMID: 11865300
  68. Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma.
    Nucl Med Rev Cent East Eur. 2013;16(1):3-8 PMID: 23677757
  69. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
    J Clin Oncol. 2014 Feb 10;32(5):431-7 PMID: 24378414
  70. Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma.
    Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1524-1530 PMID: 30847538
  71. Diagnosis of complex renal cystic masses and solid renal lesions using PET imaging: comparison of 11C-acetate and 18F-FDG PET imaging.
    Clin Nucl Med. 2014 Mar;39(3):e208-14 PMID: 24217534
  72. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Cancer Chemother Pharmacol. 2018 Apr;81(4):739-744 PMID: 29464355
  73. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.
    Mol Imaging Biol. 2005 Nov-Dec;7(6):431-9 PMID: 16307216
  74. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
    Cancer Imaging. 2015 Sep 03;15:15 PMID: 26335224
  75. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.
    Rev Esp Med Nucl. 2010 Jan-Feb;29(1):12-9 PMID: 20022140
  76. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
    J Urol. 2010 Apr;183(4):1309-15 PMID: 20171681
  77. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
    Nucl Med Rev Cent East Eur. 2018;21(2):85-91 PMID: 30070347
  78. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
    Cancer Genet. 2012 Jul-Aug;205(7-8):377-90 PMID: 22867999
  79. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):464-73 PMID: 26268680
  80. Lymph node imaging in initial staging of prostate cancer: An overview and update.
    World J Radiol. 2017 Oct 28;9(10):389-399 PMID: 29104741
  81. The clinical use of PET with (11)C-acetate.
    Am J Nucl Med Mol Imaging. 2012;2(1):33-47 PMID: 23133801
  82. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC.
    Nat Rev Urol. 2011 Mar;8(3):165-71 PMID: 21304509
  83. [1-(11)C]acetate uptake is not increased in renal cell carcinoma.
    Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):884-8 PMID: 17262213
  84. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.
    Genome Res. 2012 Nov;22(11):2089-100 PMID: 23038766
Article Info
Journal
Current urology reports
Abbr.
Curr Urol Rep
ISSN
1534-6285
DOI
10.1007/s11934-019-0932-2
Email
sidanaav@ucmail.uc.edu
Published
2019-08-29
Epub
2019-00-29
Pages
56
Language
English
Region
United States
NLM ID
100900943
Subset
IM
External Links
PubMed source DOI: 10.1007/s11934-019-0932-2 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2